[go: up one dir, main page]

WO2009095646A3 - Peptides from factor viii - Google Patents

Peptides from factor viii Download PDF

Info

Publication number
WO2009095646A3
WO2009095646A3 PCT/GB2009/000187 GB2009000187W WO2009095646A3 WO 2009095646 A3 WO2009095646 A3 WO 2009095646A3 GB 2009000187 W GB2009000187 W GB 2009000187W WO 2009095646 A3 WO2009095646 A3 WO 2009095646A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
factor viii
haemophilia
inhibitors
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/000187
Other languages
French (fr)
Other versions
WO2009095646A2 (en
Inventor
Roderick Peter Hafner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of WO2009095646A2 publication Critical patent/WO2009095646A2/en
Publication of WO2009095646A3 publication Critical patent/WO2009095646A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions comprising peptides for preventing or treating the development of inhibitors in patients with haemophilia, in particular certain peptides and / or peptide fragments derived from factor VIII.
PCT/GB2009/000187 2008-01-28 2009-01-23 Peptides from factor viii Ceased WO2009095646A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0801513.3 2008-01-28
GBGB0801513.3A GB0801513D0 (en) 2008-01-28 2008-01-28 Peptides from factor VIII

Publications (2)

Publication Number Publication Date
WO2009095646A2 WO2009095646A2 (en) 2009-08-06
WO2009095646A3 true WO2009095646A3 (en) 2010-03-11

Family

ID=39186435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/000187 Ceased WO2009095646A2 (en) 2008-01-28 2009-01-23 Peptides from factor viii

Country Status (2)

Country Link
GB (1) GB0801513D0 (en)
WO (1) WO2009095646A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458445A (en) * 2009-05-18 2012-05-16 艾匹托普技术(布里斯托尔)有限公司 FVIII-derived peptides
CN103298482A (en) * 2010-10-27 2013-09-11 巴克斯特国际公司 FVIII peptides for immune tolerance induction and immunodiagnostics

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56069B1 (en) * 2012-11-12 2017-10-31 Apitope Int Nv FACTOR VIII-derived peptides for use in the treatment of hemophilia A
EP3060242A1 (en) * 2013-10-22 2016-08-31 DBV Technologies Method of treating haemophilia by inducing tolerance to blood factors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002090542A2 (en) * 2001-05-09 2002-11-14 Departement Central De Fractionnement De La Croix-Rouge S.C.R.L. Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002090542A2 (en) * 2001-05-09 2002-11-14 Departement Central De Fractionnement De La Croix-Rouge S.C.R.L. Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458445A (en) * 2009-05-18 2012-05-16 艾匹托普技术(布里斯托尔)有限公司 FVIII-derived peptides
CN102458445B (en) * 2009-05-18 2014-06-11 艾匹托普国际股份有限公司 Peptide
CN103298482A (en) * 2010-10-27 2013-09-11 巴克斯特国际公司 FVIII peptides for immune tolerance induction and immunodiagnostics
CN103298482B (en) * 2010-10-27 2015-08-19 巴克斯特国际公司 FVIII peptides for immune tolerance induction and immunodiagnostics

Also Published As

Publication number Publication date
GB0801513D0 (en) 2008-03-05
WO2009095646A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
DE602008002693D1 (en) VACCINE PEPTIDE COMBINATIONS AGAINST CATERING ALLERGY
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2009129246A3 (en) Compositions and methods for preparing and using same
ZA201001054B (en) Peptide with reduced dimer formation
WO2009149339A3 (en) P53 activator peptides
PH12012500916B1 (en) Treatments for gastrointestinal disorders
MX2012001346A (en) Modified factor ix polypeptides and uses thereof.
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
NZ607892A (en) Tfpi inhibitors and methods of use
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
MX2010010457A (en) Recombinant rhinovirus vectors.
WO2008093058A3 (en) Peptides and their use
WO2011098778A3 (en) Peptides for vaccines against birch allergy
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
MX2011008179A (en) Peptides for vaccine.
WO2014039074A3 (en) Therapeutic compositions and related methods
WO2009095646A3 (en) Peptides from factor viii
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
IN2012DN00592A (en)
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705078

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09705078

Country of ref document: EP

Kind code of ref document: A2